Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Warfarin
Drug ID BADD_D02373
Description Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Indications and Usage **Indicated** for:[label,L6616] 1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism. 2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation. 3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement. 4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction. **Off-label** uses include: 1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.[A179182]
Marketing Status approved
ATC Code B01AA03
DrugBank ID DB00682
KEGG ID D08682
MeSH ID D014859
PubChem ID 54678486
TTD Drug ID D0E3OF
NDC Product Code 76282-328; 43353-054; 65162-764; 70518-2381; 76282-335; 70518-2382; 76282-333; 43353-023; 51407-345; 65162-762; 65162-765; 70518-2383; 71335-1786; 65162-763; 65162-767; 68788-8402; 71610-491; 71610-519; 50090-2646; 50090-5058; 70518-2717; 71610-458; 71610-462; 43353-029; 50090-2936; 51407-346; 65162-769; 43353-030; 65162-768; 70518-2394; 71610-448; 71610-490; 76282-330; 50090-2613; 51407-342; 65162-766; 70518-2816; 76282-329; 76282-331; 76282-334; 50090-3263; 71335-1824; 76282-332; 43353-021; 43353-028; 43353-053; 51407-343; 51407-344; 51407-347; 65162-761; 76282-327; 43353-033; 50090-2645
UNII 5Q7ZVV76EI
Synonyms Warfarin | 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one | Apo-Warfarin | Aldocumar | Gen-Warfarin | Warfant | Coumadin | Marevan | Warfarin Potassium | Potassium, Warfarin | Warfarin Sodium | Sodium, Warfarin | Coumadine | Tedicumar
Chemical Information
Molecular Formula C19H16O4
CAS Registry Number 81-81-2
SMILES CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Erosive oesophagitis07.04.05.0040.000042%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000334%Not Available
Orthostatic intolerance24.06.01.003; 17.05.01.007; 02.11.01.0190.000028%Not Available
Vascular stent thrombosis24.01.01.044; 08.07.05.0020.000084%Not Available
Skin haemorrhage24.07.01.103; 23.06.07.0010.000056%Not Available
Complex regional pain syndrome17.02.07.010; 12.01.12.0040.000042%Not Available
Infusion site extravasation12.07.05.008; 08.02.05.0070.000109%
Spontaneous haematoma24.07.01.054; 01.01.03.0060.000196%Not Available
Ovarian haemorrhage24.07.03.009; 21.11.02.0060.000056%
Acute interstitial pneumonitis22.01.02.0160.000056%Not Available
Treatment failure08.06.01.0170.000726%Not Available
Liver injury12.01.17.012; 09.01.07.0220.000154%Not Available
Low birth weight baby18.04.02.0030.000210%Not Available
Gastrointestinal sounds abnormal07.01.01.0020.000028%Not Available
Upper airway obstruction22.12.03.0320.000140%Not Available
Haemorrhagic erosive gastritis24.07.02.037; 07.04.03.0080.000028%Not Available
Abdominal wall haemorrhage12.01.17.002; 24.07.02.036; 07.16.05.0020.000028%Not Available
Skin mass23.07.04.0140.000042%Not Available
Brain injury19.07.03.007; 17.11.01.0030.000098%Not Available
Anorectal discomfort07.03.03.003--Not Available
Neurological decompensation17.02.05.0300.000140%Not Available
Acute kidney injury20.01.03.0160.001767%
Acquired Von Willebrand's disease01.01.01.0040.000028%Not Available
Hypoxic-ischaemic encephalopathy24.04.06.021; 22.02.02.011; 17.13.02.0060.000056%Not Available
Foetal growth restriction18.03.01.0020.000126%
Penile haematoma24.07.03.017; 21.12.01.0100.000028%Not Available
Gastrointestinal tract irritation07.08.03.0080.000028%Not Available
Functional gastrointestinal disorder07.11.01.0160.000062%Not Available
Slow speech19.19.02.004; 17.02.08.0160.000028%Not Available
Central nervous system haemorrhage24.07.04.016; 17.08.01.0350.000799%Not Available
The 18th Page    First    Pre   18 19 20 21 22    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene